Ionis Pharmaceuticals, Inc.
IONS
|
$42.1
0.62%
290K
|
Health Technology
(0.0% 1d) (-4.7% 1m) (16.6% 1y) (0.0% 2d) (2.8% 3d) (2.5% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 6,136,075,000
http://www.ionispharm.com
Sec Filling | Patents | 817 employees
(US) Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
drug discovery
add to watch list Paper trade email alert is off
Press-releases
Ionis to hold first quarter 2024 financial results webcast
Published: 2024-04-23 (Crawled : 11:00) - prnewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: 1.45%
H: 2.35%
C: 1.36%
first financial results
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
| Email alert
Add to watchlist
positive for results study
Ionis to present at upcoming investor conferences
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: -3.0%
H: 1.62%
C: 1.45%
Ionis to hold olezarsen Phase 3 data webcast
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: -0.14%
H: 3.12%
C: 2.93%
positive meeting cardiology
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
Published: 2024-03-19 (Crawled : 12:30) - biospace.com/
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: -0.33%
H: 1.89%
C: 0.64%
drug health genetic als review treatment canada submission
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Published: 2024-03-13 (Crawled : 11:00) - prnewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: 0.69%
H: 1.1%
C: -0.71%
ion224 positive treatment results study
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: 0.05%
H: 1.32%
C: 0.18%
BIIB | $202.7 4.93% 1.6M
|
Health Technology
|
| O: 0.11%
H: 1.16%
C: 0.04%
spinraza biomarker potential therapy
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
PRAX | $48.86 0.04% 50K
|
Health Technology
|
| O: 2.36%
H: 0.88%
C: -4.14%
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: -0.2%
H: 0.83%
C: -1.32%
precision update financial results
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Published: 2024-02-29 (Crawled : 14:00) - prnewswire.com
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: -0.24%
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: 0.82%
H: 0.33%
C: -3.64%
AZN | News | $71.065 0.3% 3.2M
|
Health Technology
|
| O: -0.28%
H: 0.06%
C: -1.55%
global commercial growth
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0000874015-24-000133 | 4 | 2024-03-13 | 2024-02-26 | Buy | A | 65203 | 65203 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 55% | 45% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Last 48 Hours Insiders Buying
NWFL | News | $24.0 -0.46% 4.6K
|
Finance
|
17:00
MNSB P 310 | $15.91 -2.75% 18K
|
Finance
|
15:30
TPL P 3 | $585.605 -0.38% 11K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 3.1K
|
Finance and Insurance
|
15:01
MEGI | $11.98 74K
|
|
00:30
CTRN P 29000 | $21.855 -1.69% 26K
|
Retail Trade
|
22:00
CONN | $3.735 0.95% 21K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.56 -0.51% 420K
|
Finance
|
17:30
RMCF | $3.54 2.5K
|
Consumer Non-Durables
|
20:10